Spero therapeutics announces appointment of sath shukla as chief financial officer

Cambridge, mass., dec. 17, 2020 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of satyavrat “sath” shukla, cfa, as chief financial officer, effective as of january 4, 2021.
SPRO Ratings Summary
SPRO Quant Ranking